Company: DMAC
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001437749-25-008018
Chunk: 3

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 8
Chunk 3
---
 the Sarbanes-Oxley Act of 2002                                               Filed herewith                                                                                                                                             
      31.2      Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                                                             Filed herewith                                                                                                                                             
      32.1      Certification of President and Chief Executive Officer Pursuant to Rule 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                    Furnished herewith                                                                                                                                         
      32.2      Certification of Chief Financial Officer Pursuant to Rule 18 U. S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002                                                  Furnished herewith                                                                                                                                         
     97.1#      DiaMedica Therapeutics Inc. Clawback Policy                                                                                                                                                               Incorporated by reference to Exhibit 97.1 to DiaMedica’s Annual Report on Form 10-K for the year ended December 31, 2023                                   
       101      The following materials from DiaMedica Therapeutics Inc.’s Annual Report on Form 10-K for the year ended December 31, 2024, formatted in Inline XBRL (Extensible Business Reporting Language): (i...      Filed herewith                                                                                                                                             
       104      Cover Page Interactive Data File                                                                                                                                                                          Embedded within the Inline XBRL document                                                                                                                   

  Indicates a management contract or compensatory plan or arrangement.  

  (1)      Portions of this exhibit have been redacted and are subject to an order granting confidential treatment under Rule 406 of the United States Securities Act of 1933, as amended (File No. 333-2283...  

103

  Item 16.      Form 10-K Summary  
 ───────────────────────────────────

None.

104

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

                            DIAMEDICA THERAPEUTICS INC.                                             
  Date: March 17, 2025      By:                              /s/ Rick Pauls                         
                                                             Rick Pauls                             
                                                             President and Chief Executive Officer  

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoint